Glenmark Pharmaceuticals Limited

NSEI:GLENMARK 주식 보고서

시가총액: ₹400.1b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Glenmark Pharmaceuticals 배당금

배당금 기준 확인 2/6

Glenmark Pharmaceuticals 은(는) 현재 수익률이 0.2% 인 배당금 지급 회사입니다.

주요 정보

0.2%

배당 수익률

-4%

지급 비율

업계 평균 수익률0.7%
다음 배당금 지급일n/a
전 배당일n/a
주당 배당금₹2.500
주당 순이익-₹67.30
3년 후 배당 수익률 예측0.2%

최근 배당금 업데이트

Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50

Sep 17
Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Aug 30
Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Recent updates

Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Aug 06
Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Jun 16
Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value

May 08
Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value

Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt

Mar 09
Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?

Dec 07
Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Sep 23
Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50

Sep 17
Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Aug 30
Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Aug 28
A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt

Jul 03
We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt

A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

May 28
A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet

Mar 22
Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet

Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Feb 14
Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued

Oct 12
An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Sep 21
Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Aug 29
Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

Jun 20
We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings

Jun 04
There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings

An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued

May 05
An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued

If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late

Mar 25
If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late

A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Jan 18
A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

Dec 13
We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: GLENMARK 의 주당 배당금은 지난 10 년 동안 안정적이었습니다.

배당금 증가: GLENMARK 의 배당금 지급은 지난 10 년 동안 증가했습니다.


시장 대비 배당 수익률

Glenmark Pharmaceuticals 시장 대비 배당 수익률
GLENMARK 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트배당 수익률
회사 (GLENMARK)0.2%
시장 하위 25% (IN)0.3%
시장 상위 25% (IN)1.1%
업계 평균 (Pharmaceuticals)0.7%
3년 후 애널리스트 예측 (GLENMARK)0.2%

주목할만한 배당금: GLENMARK 의 배당금( 0.2% )은 Indian 시장( 0.27% ).

고배당: GLENMARK 의 배당금( 0.2% )은 Indian 시장에서 배당금 지급자의 상위 25% 1.12% ).


주주에 대한 수익 배당금

수익 보장: GLENMARK 배당금을 지급하고 있지만 회사는 수익성이 없습니다.


주주에 대한 현금 배당금

현금 흐름 범위: GLENMARK 배당금을 지급하고 있지만 회사에는 잉여현금흐름이 없습니다.


강력한 배당금 지급 기업 알아보기